# Alvocidib Biomarker-driven Phase 2 AML Study

> **NCT02520011** · PHASE2 · TERMINATED · sponsor: **Sumitomo Pharma America, Inc.** · enrollment: 104 (actual)

## Conditions studied

- Acute Myeloid Leukemia

## Interventions

- **DRUG:** Alvocidib
- **DRUG:** Cytarabine
- **DRUG:** Mitoxantrone

## Key facts

- **NCT ID:** NCT02520011
- **Lead sponsor:** Sumitomo Pharma America, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2016-03-14
- **Primary completion:** 2020-02-12
- **Final completion:** 2020-02-12
- **Target enrollment:** 104 (ACTUAL)
- **Why stopped:** Due to slow enrollment, the extensive time projected to conclude the study hypothesis rendered the study no longer reasonably feasible to complete.
- **Last updated:** 2023-11-15


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02520011

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02520011, "Alvocidib Biomarker-driven Phase 2 AML Study". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT02520011. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*